AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Enhertu (trastuzumab deruxtecan) in the adjuvant treatment of adults with resected HER2-positive breast cancer.
AstraZeneca (NASDAQ:AZN) has reportedly engaged in early-stage negotiations regarding a potential merger with Bristol Myers Squibb (NYSE:BMY).
AstraZeneca (NYSE:AZN) reported second-quarter core EPS of $2.63, up 21%, as oncology and rare-disease sales grew.
On this episode of Stock Movers: - Forte Bioscience (FBRX) is soaring as Argenx SE agreed to buy Forte Biosciences Inc. for about $2.2 billion in cash to expand its portfolio of immunology medicines. - Astrazeneca (AZN) shares rose after it reported higher-than-expected profit, buoyed by blockbuster cancer medicines, with earnings per share rising 21% to $2.63 last quarter. - Paramount Skydance (PSKY) shares are reacting to news that it paused its blockbuster deal for Warner Bros.
AstraZeneca has explored an acquisition of Bristol Myers Squibb, according to people familiar with the matter. It's unclear if discussions are ongoing or whether they will result in a transaction, the people cautioned. A representative for AstraZeneca declined to comment and Bristol Myers Squibb couldn't immediately be reached for comment on the talks. Bloomberg's Manuel Baigorri reports.
_1447241_640x360_2508622403601-640x360.webp&w=3840&q=75)
